about
The telomeric poly(ADP-ribose) polymerase, tankyrase 1, contains multiple binding sites for telomeric repeat binding factor 1 (TRF1) and a novel acceptor, 182-kDa tankyrase-binding protein (TAB182)HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycleTelomere elongation by a mutant tankyrase 1 without TRF1 poly(ADP-ribosyl)ationFunctional subdomain in the ankyrin domain of tankyrase 1 required for poly(ADP-ribosyl)ation of TRF1 and telomere elongationInvolvement of 14-3-3 proteins in nuclear localization of telomeraseReport on the use of non-clinical studies in the regulatory evaluation of oncology drugsPredicting Risk at the End of the End: Telomere G-tail as a BiomarkerInhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact.Pim-1 negatively regulates the activity of PTP-U2S phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cellsInvolvement of CD45 in adhesion and suppression of apoptosis of mouse malignant T-lymphoma cellsTRF1 ensures the centromeric function of Aurora-B and proper chromosome segregation.Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancerExpression of mutant RPA in human cancer cells causes telomere shortening.Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole.Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.Reprogramming suppresses premature senescence phenotypes of Werner syndrome cells and maintains chromosomal stability over long-term culture.ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer.Telomeric repeat-containing RNA/G-quadruplex-forming sequences cause genome-wide alteration of gene expression in human cancer cells in vivoTelomere length influences cancer cell differentiation in vivo.Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb.G-quadruplex ligand-induced DNA damage response coupled with telomere dysfunction and replication stress in glioma stem cells.Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.Senescence from glioma stem cell differentiation promotes tumor growthDesign and synthesis of a berberine dimer: a fluorescent ligand with high affinity towards G-quadruplexes.TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression.Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells.Evaluation of the interaction between long telomeric DNA and macrocyclic hexaoxazole (6OTD) dimer of a G-quadruplex ligand.A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor.Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions.Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer.The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinomaFJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis.ASK1 mediates apoptotic cell death induced by genotoxic stress.Development of a gene expression database and related analysis programs for evaluation of anticancer compounds.TRF1 mediates mitotic abnormalities induced by Aurora-A overexpression.The eleventh Korea-Japan-Germany joint symposium on cancer and ageing research.Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991.
P50
Q24292328-1DB57B40-D2E8-421B-8C25-79AA990D7188Q24296105-51A3F0DF-66EF-42BC-BB35-BC454F609D16Q24307747-FBA6FEFA-909F-4A05-A332-AC5834D377D4Q24607672-95F10D2D-2FAF-4B56-82C3-2357B83216DEQ24685623-E6E751BB-D8F7-43DC-9CB0-8DE70C5FD2C7Q26766039-F364E2B7-C922-4177-95D4-1AF30AB5DAA1Q26783116-D46EC921-2CC0-41B5-861E-F292D8563979Q27852121-BA7D18C2-8208-47C6-A859-EC18400366FEQ28190037-540742E7-D297-410B-B28B-3E3CEA963E7CQ28584774-165CABEB-E3EB-4613-8E04-AA3786C6FAB9Q30580516-B9A6C8C9-1D36-4D1E-A93B-91774E24410DQ33432141-6D287CD2-CA9A-46FB-8D5F-91BBC4A0F4B6Q33530050-6F88E80B-C167-494B-96EB-6F78102ABDF6Q33658256-7C33636C-8B02-499E-A4D5-9C57EF476E80Q33804001-544EEC59-0C94-4770-A9EF-24A10B037119Q34384662-071D92FC-B4F8-40C1-89DB-F66D0022B2C3Q34498165-0FCA3B16-3754-4105-BC89-A8DE2C7A8475Q34657399-694FFCE1-2C4B-4C6A-BB6A-E5B446EAC9F5Q35131119-7E23CDD0-6924-4460-A578-27BD94CBF402Q37036345-BC11614B-C5A7-4430-A8C4-59362CD7D7FAQ37494834-232EA48E-DF95-4866-BBB5-4C6D324CBC59Q37524887-653A228B-497B-4D8B-BCD0-C171DE445420Q38463905-34B0616F-A1F9-484C-9C64-CF7F402CE61FQ38700323-F6FBD62E-D65D-4C8A-B5C3-8DF27F3DDB86Q38717206-3E27CB19-9107-4FA4-BB60-C8A79E73F880Q38802705-6E2B759C-2442-4C63-8CD7-42135A53591EQ38974413-5C96673E-B2FE-4E94-AE2A-4B340AF2DF29Q38981592-DCF3DE14-C193-452A-8ABB-4D05A16B72DCQ39047815-0117FFAC-E1A4-4A70-80D1-B92325AFA758Q39166878-045E2A6E-0833-4EF7-8788-DBC26AC6D1CEQ39730349-2C511AD7-6DC9-49DC-AB6C-8CD668870B93Q39937384-D327E1A1-AD2F-477F-AA57-E2BC1B0A03CAQ40316288-B2B8C380-A9BC-47AF-81AB-1669FD317EE2Q40368929-764001E4-D519-4207-B49B-994CAA904659Q40933124-9FE1523A-E36D-48E8-BD98-B1CE7DCE7BF1Q40976753-6D192D4C-3277-43AD-9B59-974A9578C118Q42677922-7FF923A4-9351-4E11-A718-0C1584EAA101Q43160215-484A9EE9-E8F8-46B3-B54B-6F1A08044B69Q43454169-FEB77A45-5F14-4534-8D2B-9D5A240C70D6Q44246932-401E4145-93D8-4751-A90B-FD09E35F9D80
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hiroyuki Seimiya
@ast
Hiroyuki Seimiya
@en
Hiroyuki Seimiya
@es
Hiroyuki Seimiya
@nl
Hiroyuki Seimiya
@sl
type
label
Hiroyuki Seimiya
@ast
Hiroyuki Seimiya
@en
Hiroyuki Seimiya
@es
Hiroyuki Seimiya
@nl
Hiroyuki Seimiya
@sl
prefLabel
Hiroyuki Seimiya
@ast
Hiroyuki Seimiya
@en
Hiroyuki Seimiya
@es
Hiroyuki Seimiya
@nl
Hiroyuki Seimiya
@sl
P106
P21
P31
P496
0000-0003-3314-9736
P569
2000-01-01T00:00:00Z